Immuno-oncology pioneer sold for up to 464 Million Euros
MSD to acquire Rigontec GmbH
MSD (Merck, Sharp & Dohme Corp.) and Rigontec announced on September 6, 2017 that MSD will acquire Rigontec. Rigontec is a pioneer in accessing the retinoic acid-inducible gene I (RIG-I) pathway, part of the innate immune system, as a novel and distinct approach in cancer immunotherapy to induce both immediate and long-term anti-tumor immunity. Under the terms of the agreement, MSD, through a subsidiary, will make an upfront cash payment of 115 million Euros to Rigontec’s shareholders; based on the attainment of certain clinical, development, regulatory and commercial milestones, MSD may make additional contingent payments of up to 349 million Euros. The transaction is subject to certain closing conditions.
Dr. Christian Schetter,
CEO, Rigontec GmbH
“Rigontec’s immuno-oncology approach of engaging the innate immune system to safely eliminate cancer cells complements our strategy and our current pipeline,” said Dr. Eric Rubin, vice president of early-stage development, clinical oncology, MSD Research Laboratories. “We are eager to build upon Rigontec’s science as we continue our efforts in bringing forward meaningful advances for patients with cancer.”
“MSD is a true pioneer in the immuno-oncology space and we are thrilled that our technology will benefit from their experience and leadership position,” said Dr. Christian Schetter, CEO of Rigontec. “We are confident that our programs will be in the best hands and that the team at MSD will continue the work we established with our scientific founders and brought into the clinic within three years since our foundation as a company.”